September 20, 2016 – (Kite) – “Kite Pharma, Inc., a clinical-stage biopharmaceutical company focused on developing engineered autologous T-cell therapy (eACTâ„¢) products for the treatment of cancer, today announced that the Company has entered into an exclusive, worldwide license with the National Institutes of Health (NIH) for intellectual property related to multiple T-cell receptor (TCR) based product candidates for the treatment of tumors expressing mutated KRAS antigens.” Read Full Press Release